Biotech and Pharma Industry News | BioPharma Dive
WEBModerna to cut costs, trim pipeline in R&D revamp. As part of a broad restructuring, the company plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a …
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Biotech M&A has plateaued. Track the deals that are happening …
WEB4 days ago · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB6 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
FDA lifts partial hold on study of BioNTech-partnered ADC
WEBAug 19, 2024 · When BioNTech announced the partial hold on June 17, it cited “safety findings including grade 5 adverse events,” a term trial investigators typically use to describe deaths from side effects. Data presented at a medical meeting earlier that month noted the deaths of three trial participants given doses higher than 3 mg/kg.
BridgeBio sends rare disease drugs to new company
WEBAug 21, 2024 · The formation of new company GondolaBio was disclosed by BridgeBio Pharma in a securities filing on Aug. 21, 2024. VisualCommunications via Getty Images. BridgeBio Pharma has transferred several preclinical and early clinical-stage drugs to a new company, GondolaBio, that’s drawn $300 million in …
The next era of Greater Boston’s biotech boom | BioPharma Dive
WEBNov 22, 2022 · The next era of Greater Boston’s biotech boom. Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs. Published November 22, 2022 • By Karissa Waddick , Shaun Lucas and Julia Himmel. A map of the Kendall Square neighborhood in ...
Clinical Trial News - BioPharma Dive
WEB5 days ago · Keytruda fails lung and skin cancer trials, limiting further expansion. The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion. By Jonathan Gardner • Aug. 29, 2024.
8 key clinical trials to watch for the rest of 2021
WEBJun 21, 2021 · The first half of 2021 was historic for biotech. The Food and Drug Administration cleared the first new Alzheimer's drug in nearly two decades, a controversial decision with far-reaching consequences. Multiple effective coronavirus vaccines and antibody drugs helped bring the pandemic under control in the U.S., while the first-ever treatment for a common genetic driver of cancer won approval.
Skip to content